Eco Scientific has expressed concerns that some members of the population could be at increased risk from COVID-19 treatments if they have the G6PD (Glucose-6-Phosphate Dehydrogenase deficiency.
The company claims that if Chloroquine is used to treat patients with such a deficiency, it could cause added problems – causing low levels of O2 levels in their blood.
A G6PD blood test – more usually used for babies and pre-cancer treatment – can be carried out before treatment. Eco Scientific supply Pointe G6PD test kits to the NHS and can be contacted here.
